AFP and hepatocellular carcinoma: Alpha fetoprotein (AFP) is a well-known diagnostic and prognostic biomarker used clinically for HCC, and a recent study revealed that posttreatment AFP levels could be used to predict HCC occurrence in advanced chronic liver disease from European and Japanese patients who achieved SVR after DAA treatment [20,21,24].